Edition:
India

CASI Pharmaceuticals Inc (CASI.OQ)

CASI.OQ on NASDAQ Stock Exchange Capital Market

6.89USD
1:30am IST
Change (% chg)

$0.43 (+6.66%)
Prev Close
$6.46
Open
$6.55
Day's High
$6.95
Day's Low
$6.50
Volume
89,066
Avg. Vol
125,542
52-wk High
$7.60
52-wk Low
$0.91

Latest Key Developments (Source: Significant Developments)

CASI Pharmaceuticals Q4 Loss Per Share $0.08
Thursday, 29 Mar 2018 

March 29 (Reuters) - CASI Pharmaceuticals Inc ::CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.08.AS OF DECEMBER 31, 2017, CASI HAD CASH AND CASH EQUIVALENTS OF APPROXIMATELY $43.5 MILLION.  Full Article

Casi Pharmaceuticals Files For Stock Shelf Of Upto $100 Million
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Casi Pharmaceuticals Inc ::CASI PHARMACEUTICALS INC FILES FOR STOCK SHELF OF UPTO $100 MILLION - SEC FILING.  Full Article

Casi pharmaceuticals Q3 loss per share $0.03
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Casi Pharmaceuticals Inc :Casi Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.03.As of September 30, 2017, Casi had cash and cash equivalents of approximately $21.6 million​.  Full Article

Casi Pharmaceuticals Q2 loss per share $0.08
Monday, 15 Aug 2016 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports second quarter 2016 financial results .Q2 loss per share $0.08.  Full Article

Casi Pharmaceuticals reports Q1 loss per share $0.04
Friday, 13 May 2016 

Casi Pharmaceuticals Inc : Casi Pharmaceuticals reports first quarter 2016 financial results .Q1 loss per share $0.04.  Full Article

BRIEF-CASI Pharma Says Advisory Committee to Review Evomela Between April 25-26

* CASI PHARMACEUTICALS - RECEIPT OF LETTER FROM CENTER FOR DRUG EVALUATION FOR INJECTION SCHEDULED FOR REVIEW BY ADVISORY COMMITTEE